Current and novel therapeutic options for irritable bowel syndrome management - ScienceDirect
Genetics of irritable bowel syndrome: shifting gear via biobank-scale studies | Nature Reviews Gastroenterology & Hepatology
JCM | Free Full-Text | Pharmacotherapy for Irritable Bowel Syndrome
Elucidating the putative link between prefrontal neurotransmission, functional connectivity, and affective symptoms in irritable bowel syndrome | Scientific Reports
Understanding and Managing Pain in Irritable Bowel Syndrome (IBS) - About IBS
PDF) Centrally Acting Therapies for Irritable Bowel Syndrome
Medications for Irritable Bowel Syndrome and Other Gastrointestinal Problems | Basicmedical Key
Guanylate cyclase-C agonists as peripherally acting treatments of chronic visceral pain: Trends in Pharmacological Sciences
Class of medicines applied in current IBS pharmacotherapy | Download Table
Moving beyond simple irritable bowel syndrome to chronic abdominal pain | New Zealand Doctor
GIT 4th IBS 2016 with CME Qs.
Abdominal Pain in Irritable Bowel Syndrome (IBS) | Anesthesia Key
Efficacy of soluble fibre, antispasmodic drugs, and gut–brain neuromodulators in irritable bowel syndrome: a systematic review and network meta-analysis - The Lancet Gastroenterology & Hepatology
PDF) Centrally Acting Therapies for Irritable Bowel Syndrome
New treatments for IBS | Nature Reviews Gastroenterology & Hepatology
Frontiers | Luminally Acting Agents for Constipation Treatment: A Review Based on Literatures and Patents
Treatments targeting putative mechanisms in irritable bowel syndrome | Nature Reviews Gastroenterology & Hepatology
Choosing and avoiding central neuromodulators for FGIDs based on... | Download Table
GIT 4th IBS 2017
Central neuromodulators-dosage | Download Table
Frontiers | Current Treatment Options and Therapeutic Insights for Gastrointestinal Dysmotility and Functional Gastrointestinal Disorders
Towards a systems view of IBS | Nature Reviews Gastroenterology & Hepatology
PDF) A Second Generation of Centrally Acting Antihypertensive Agents Act on Putative I1-Imidazoline Receptors
